705 related articles for article (PubMed ID: 26607904)
1. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
2. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
3. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
4. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
5. Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: a role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation.
Kumar A; Kant S; Singh SM
Toxicol Appl Pharmacol; 2013 Nov; 273(1):196-208. PubMed ID: 24051182
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
7. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.
Stockwin LH; Yu SX; Borgel S; Hancock C; Wolfe TL; Phillips LR; Hollingshead MG; Newton DL
Int J Cancer; 2010 Dec; 127(11):2510-9. PubMed ID: 20533281
[TBL] [Abstract][Full Text] [Related]
8. Nonthermal plasma induces head and neck cancer cell death: the potential involvement of mitogen-activated protein kinase-dependent mitochondrial reactive oxygen species.
Kang SU; Cho JH; Chang JW; Shin YS; Kim KI; Park JK; Yang SS; Lee JS; Moon E; Lee K; Kim CH
Cell Death Dis; 2014 Feb; 5(2):e1056. PubMed ID: 24525732
[TBL] [Abstract][Full Text] [Related]
9. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
Kim EH; Baek S; Shin D; Lee J; Roh JL
Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
11. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
Kim EH; Jang H; Roh JL
Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
[TBL] [Abstract][Full Text] [Related]
12. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.
Kluza J; Corazao-Rozas P; Touil Y; Jendoubi M; Maire C; Guerreschi P; Jonneaux A; Ballot C; Balayssac S; Valable S; Corroyer-Dulmont A; Bernaudin M; Malet-Martino M; de Lassalle EM; Maboudou P; Formstecher P; Polakowska R; Mortier L; Marchetti P
Cancer Res; 2012 Oct; 72(19):5035-47. PubMed ID: 22865452
[TBL] [Abstract][Full Text] [Related]
15. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.
Roh JL; Kim EH; Park JY; Kim JW; Kwon M; Lee BH
Oncotarget; 2014 Oct; 5(19):9227-38. PubMed ID: 25193861
[TBL] [Abstract][Full Text] [Related]
16. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
Roh JL; Kim EH; Park JY; Kim JW
Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
[TBL] [Abstract][Full Text] [Related]
18. Multi-modality imaging to assess metabolic response to dichloroacetate treatment in tumor models.
Neveu MA; De Preter G; Joudiou N; Bol A; Brender JR; Saito K; Kishimoto S; Grégoire V; Jordan BF; Krishna MC; Feron O; Gallez B
Oncotarget; 2016 Dec; 7(49):81741-81749. PubMed ID: 28082726
[TBL] [Abstract][Full Text] [Related]
19. Novel molecular mechanisms of antitumor action of dichloroacetate against T cell lymphoma: Implication of altered glucose metabolism, pH homeostasis and cell survival regulation.
Kumar A; Kant S; Singh SM
Chem Biol Interact; 2012 Jul; 199(1):29-37. PubMed ID: 22705712
[TBL] [Abstract][Full Text] [Related]
20. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells.
Xie J; Wang BS; Yu DH; Lu Q; Ma J; Qi H; Fang C; Chen HZ
Int J Oncol; 2011 Feb; 38(2):409-17. PubMed ID: 21132264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
